Company intelligence / Profile preview

Brenner

Ownership: Private
Development stage: Other

Overview

Brenner is a biotechnology company focused on the development of novel therapeutics that target nicotinamide adenine dinucleotide (NAD+) metabolism. The company's research is centered on the work of Dr. Charles Brenner, a leading expert in NAD+ biology, and aims to address metabolic, aging-related, and neurodegenerative diseases. Brenner's pipeline includes small molecule candidates designed to restore NAD+ levels and improve cellular health. The company is currently in the pre-clinical stage of development, with a focus on advancing its lead programs toward clinical trials.

Therapeutic areas: NeurologyMetabolic DisordersOther
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Brenner.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brenner.

Explore the full profile